United States Weight Loss Devices Market 2025: Top Manufacturers & Growth Opportunities | Leading Companies are ReShape Lifesciences, Inc, Helioscopie Medical Implants, Allurion, Spatz FGIA, Obalon Therapeutics, Inc

Around 70% of U.S. adults are overweight or obese, with 36% classified as obese, marking the highest rates ever recorded by NHANES. Obesity is a major health concern linked to heart disease, stroke, diabetes, and increased cancer risk.

DataM Intelligence has released its latest report on the "Weight Loss Devices Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

According to the World Health Organization (WHO), around 2 billion adults worldwide are overweight, with 650 million classified as obese (BMI ≥30 kg/m2). This means 39% of adults aged 18 and above are overweight (39% men, 40% women), and 13% are obese. If current trends persist, by 2025, an estimated 2.7 billion adults will be overweight, including over 1 billion with obesity and 177 million severely affected.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/weight-loss-devices-market?kb

United States: Recent Industry Developments
✅ October 2025: Boston Scientific introduced a next-generation minimally invasive gastric balloon system for obesity management.
✅ September 2025: ReShape Lifesciences expanded the availability of its adjustable gastric band technology across U.S. clinics.
✅ August 2025: The FDA approved new non-invasive body contouring devices using RF and laser-assisted fat reduction technologies.

Japan: Recent Industry Developments
✅ October 2025: Allurion Technologies collaborated with Japanese hospitals to launch swallowable gastric balloons for weight loss.
✅ September 2025: Growing demand for wearable fat-tracking and calorie-monitoring devices integrated with AI-based analytics.
✅ August 2025: Local medical device firms advanced non-surgical body contouring solutions catering to Japan's aging population.

Key Player:

ReShape Lifesciences, Inc, Helioscopie Medical Implants, Allurion, Spatz FGIA, Obalon Therapeutics, Inc, Medsil, Endalis, Silimed, Ethicon, Inc, Millenium Surgical Corporation, Zhengzhou YKinspection Enterprise Co., Ltd., Chongqing Xishan Science & Technology Co., Ltd, Guangzhou Lety Medical Limited

Latest M&A

While pharmaceutical M&A in obesity drugs has been very active (e.g., Pfizer's $10B Metsera acquisition), M&A specifically targeting weight loss devices is less prominent but notable expansions include partnerships between device firms and pharma companies to integrate drug-device combination therapies.​

Some medical device companies expanded their obesity device portfolios with acquisitions of innovative startups developing non-invasive fat reduction and gastric therapy devices.

Forecast Projection:

The global Weight Loss Devices market is set to witness strong growth from 2025 to 2032. After maintaining steady momentum in 2024, the market is expected to accelerate as key industry players implement strategic initiatives to boost adoption. Companies that adapt to these emerging trends will be well-positioned to capture new opportunities and enhance their revenue potential throughout the forecast period.

Market Intelligence Research Process:

The Weight Loss Devices Market Report by DataM Intelligence offers a comprehensive analysis built on a mix of primary and secondary research. It explores key factors driving the industry, including government policies, market trends, competitive landscape, technological advancements, and upcoming innovations. This in-depth study uncovers both growth opportunities and potential challenges, helping businesses navigate market fluctuations and make data-driven decisions for sustainable success.

FDA Approvals

In addition to drugs, the FDA approved new or updated weight loss device clearances including medical devices for gastric stimulation and fat reduction therapy in 2025.​

The Signos AI-based CGM platform's FDA clearance marks a regulatory milestone for AI-enabled weight management devices.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=weight-loss-devices-market?kb

Key Segmentations:

By Type: (Gastric band, Gastric balloon system, Electrical stimulation system, Gastric emptying system, Others)

By Application: (Hospitals, Clinics, Household, Others)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/weight-loss-devices-market?kb

Latest News & Product Launches

FDA approved Signos Glucose Monitoring System in March 2025, combining continuous glucose monitoring (CGM) with AI to help users manage weight via personalized lifestyle guidance; this OTC device is first of its kind targeting non-diabetic individuals aiming for weight loss.​

Non-invasive therapeutic devices such as gastric balloons, neurostimulation devices, and cryolipolysis machines continue product launches targeting moderate obesity patient segments.​

Emerging devices emphasize optimization of patient adherence, remote monitoring capability, and integration with digital health platforms.​

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/weight-loss-devices-market?kb

Reimbursement

Reimbursement coverage for weight loss devices remains region-specific; Medicare and private insurers have started coverage for select FDA-cleared obesity devices (gastric balloons, neuromodulation) and certain wearable digital therapeutics.​

Wellness reimbursement programs in the U.S., such as those covering wellness trackers and diet coaching technology, have expanded to include AI-based glucose monitoring aids like Signos up to $300 annually.​

Challenges remain in payer acceptance and pricing for emerging devices, especially digital therapies requiring demonstration of sustained clinical outcomes.

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.